Почетна › Hronična limfocitna leukemija › Вашингтон

Kliničke studije za Hronična limfocitna leukemija u državi Вашингтон

27 studija za Hronična limfocitna leukemija traži učesnike na lokacijama u državi Вашингтон.

Gradovi u državi Вашингтон

Zvanični tekst studije (na engleskom)

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

FHCC Overlake, Bellevue
Swedish Cancer Institute-Edmonds, Edmonds
Swedish Cancer Institute-Issaquah, Issaquah
и још 7

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04269902

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Medical Oncology Associates - Spokane, Spokane

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07342478

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

Vista Oncology ( Site 5449), Olympia
Medical Oncology Associates, PS ( Site 5406), Spokane

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT05947851

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Providence Regional Cancer System-Aberdeen, Aberdeen
PeaceHealth Saint Joseph Medical Center, Bellingham
Providence Regional Cancer System-Centralia, Centralia
и још 20

Тражи се учесникОпсервациона студијаЗдраве особе су добродошле

Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Swedish Cancer Institute-Edmonds, Edmonds
Swedish Medical Center-First Hill, Seattle

Тражи се учесникФаза 3

Узраст 65 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07321652

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Fred Hutchinson Cancer Center, Seattle

Тражи се учесникФаза 2

Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07221500

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Fred Hutch/University of Washington Cancer Consortium, Seattle

Тражи се учесникФаза 2

Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT06839053

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle

Тражи се учесникФаза 2

Узраст од 18 до 80 · Оба пола · Ажурирано 30. 10. 2026. · NCT06520098

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Fred Hutch/University of Washington Cancer Consortium, Seattle

Тражи се учесникФаза 2

Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT07194980

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

Fred Hutchinson Cancer Research Center, Seattle

Тражи се учесникФаза 1/2

Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06697184

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

Fred Hutch/University of Washington Cancer Consortium, Seattle

Тражи се учесникФаза 2

Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT04941716

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Swedish Medical Center Swedish Cancer Institute First Hill Campus, Seattle
Northwest Cancer Specialist, Pc(Us Oncology Research), Vancouver

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT06943872

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Fred Hutch Cancer Center, Seattle

Тражи се учесникФаза 1

Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT06528301

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Fred Hutchinson Cancer Research Center, Seattle

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT07648264

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Swedish Cancer Institute, Edmonds Campus ( Site 0072), Edmonds
Swedish Cancer Institute, Issaquah Campus ( Site 0073), Issaquah
Swedish Medical Center-Swedish Cancer Institute ( Site 0071), Seattle
и још 1

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06136559

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Fred Hutchinson Cancer Research Center, Seattle

Тражи се учесникФаза 1/2

Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT05006716

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

Study Site 103, Tacoma

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT07582432

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Research Site, Seattle

Тражи се учесникФаза 1/2

Узраст 18 и старији · Оба пола · Ажурирано 30. 9. 2026. · NCT06542250

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Fred Hutchinson Cancer Research Center, Seattle

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT07277231

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Fred Hutchinson Cancer Research Center, Seattle
Summit Cancer Centers, Spokane
Northwest Medical Specialties, Tacoma

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT06973187

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Medical Oncology Associates, PS, Spokane

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 17. 8. 2026. · NCT05254743

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Fred Hutch/University of Washington Cancer Consortium, Seattle

Тражи се учесникФаза 2Здраве особе су добродошле

6 Months · Оба пола · Ажурирано 29. 5. 2026. · NCT04195633

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Vista Oncology - East Olympia /ID# 267337, Olympia
Northwest Medical Specialties Tacoma /ID# 266327, Tacoma

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 9. 4. 2026. · NCT06428019

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Swedish Cancer Institute, Seattle

Тражи се учесникФаза 4

Узраст 18 и старији · Оба пола · Ажурирано 2. 3. 2026. · NCT06876649

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Swedish Cancer Institute, Seattle

Тражи се учесникФаза 4

Узраст 18 и старији · Оба пола · Ажурирано 2. 3. 2026. · NCT06876662

Study of SGR-1505 in Mature B-Cell Neoplasms

Fred Hutchinson Cancer Center, Seattle

Тражи се учесникФаза 1

Узраст 18 и старији · Оба пола · Ажурирано 13. 2. 2026. · NCT05544019

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Swedish Cancer Institute, Seattle

Тражи се учесникФаза 1

Узраст 18 и старији · Оба пола · Ажурирано 2. 10. 2025. · NCT05780034

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.